^
    No biomarker
    CLL
    zanubrutinib
    Sensitive
    :
    A1
    BeiGene Press Release - 1wk
    BCR-ABL1 fusion
    ALL
    ponatinib
    Sensitive
    :
    A1
    Int J Hematol - 1wk
    CRLF2 rearrangement
    ALL
    ruxolitinib
    Sensitive
    :
    C2
    Leukemia - 1wk
    No biomarker
    AML
    azacitidine oral
    Sensitive
    :
    A1
    Bristol-Myers Squibb Press Release - 2wk
    No biomarker
    AML
    venetoclax
    Sensitive
    :
    A1
    Roche Press Release - 2wk
    IDH2 mutation + SRSF2 mutation
    AML
    venetoclax
    Sensitive
    :
    C3
    Blood Adv - 2wk
    NRAS mutation + U2AF1 mutation
    AML
    venetoclax
    Resistant
    :
    C3
    Blood Adv - 2wk
    KRAS mutation + U2AF1 mutation
    AML
    venetoclax
    Resistant
    :
    C3
    Blood Adv - 2wk
    No biomarker
    CML
    bosutinib
    Sensitive
    :
    A2
    Int J Hematol - 3wk
    FLT3-ITD mutation
    AML
    quizartinib
    Sensitive
    :
    C2
    Haematologica - 3wk
    CD20 positive
    CLL
    Truxima (rituximab biosimilar)
    Sensitive
    :
    A1
    FLT3 mutation
    AML
    gilteritinib
    Sensitive
    :
    A1
    IDH2 mutation
    AML
    enasidenib
    Sensitive
    :
    A1
    No biomarker
    AML
    glasdegib
    Sensitive
    :
    A1
    No biomarker
    B Acute Lymphoblastic Leukemia
    tisagenlecleucel-T
    Sensitive
    :
    A1
    No biomarker
    Childhood B Acute Lymphoblastic Leukemia
    tisagenlecleucel-T
    Sensitive
    :
    A1
    No biomarker
    CLL
    rituximab + ibrutinib
    Sensitive
    :
    A1
    No biomarker
    AML
    cytarabine/daunorubicin liposomal formulation
    Sensitive
    :
    A1
    Chr del(17p)
    CLL
    venetoclax + obinutuzumab
    Sensitive
    :
    A1
    TP53 mutation
    CLL
    venetoclax + obinutuzumab
    Sensitive
    :
    A1
    No biomarker
    CLL
    venetoclax + obinutuzumab
    Sensitive
    :
    A1
    BCR-ABL1 fusion
    CML
    dasatinib
    Sensitive
    :
    A1
    No biomarker
    CLL
    ICP-022
    Sensitive
    :
    A1
    FLT3 mutation
    AML
    midostaurin
    Sensitive
    :
    A1
    CD33 positive
    AML
    gemtuzumab ozogamicin
    Sensitive
    :
    A1
    BCR-ABL1 fusion
    ALL
    imatinib
    Sensitive
    :
    A1
    No biomarker
    CML
    omacetaxine mepesuccinate
    Sensitive
    :
    A1
    CD22 positive
    B Acute Lymphoblastic Leukemia
    inotuzumab ozogamicin
    Sensitive
    :
    A1
    BCR-ABL1 fusion
    B Acute Lymphoblastic Leukemia
    inotuzumab ozogamicin
    Sensitive
    :
    A1
    CD20 expression
    CLL
    rituximab-arrx
    Sensitive
    :
    A1
    BCR-ABL1 T315I
    CML
    ponatinib
    Sensitive
    :
    A1
    BCR-ABL1 T315I
    ALL
    ponatinib
    Sensitive
    :
    A1
    No biomarker
    ALL
    blinatumomab
    Sensitive
    :
    A1
    No biomarker
    B Acute Lymphoblastic Leukemia
    blinatumomab
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES